Linezolid-resistant Staphylococcus cohnii, Greece.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. First Report ofTransboundary and emerging diseases · 2024
   Article
2. Spread of clonal linezolid-resistant Staphylococcus epidermidis in an intensive care unit associated with linezolid exposure.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020
   Article
3. Bacteremia due to Staphylococcus cohnii ssp. urealyticus caused by infected pressure ulcer: case report and review of the literature.Sao Paulo medical journal = Revista paulista de medicina · 2013
   Review
4. Linezolid Resistance in Staphylococci.Pharmaceuticals (Basel, Switzerland) · 2010
   Review
5. Polyphyletic emergence of linezolid-resistant staphylococci in the United States.Antimicrobial agents and chemotherapy · 2010
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

9 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as